We bring you the latest news from the healthcare about the health care in the United Kingdom.

zondag 4 november 2018

The Lancet: [Articles] Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiog...

[Articles] Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of ixekizumab.
Read more

[Comment] Learning from the youngsters: ixekizumab in active ankylosing spondylitis
The COAST-V study published by Désirée van der Heijde and colleagues in The Lancet1 shows that ixekizumab, a monoclonal antibody that selectively targets interleukin (IL)-17A, is efficacious in patients with ankylosing spondylitis (also known as radiographic axial spondyloarthritis) who have previously been untreated with biological disease-modifying antirheumatic drugs (bDMARDs). Ixekizumab has already followed the other IL-17A antibody, secukinumab, in two other indications, psoriasis and psoriatic arthritis, and it seems likely that an approval for radiographic axial spondyloarthritis will follow on the basis of the evidence provided in this Article.
Read more

[Comment] A new opportunity after migraine treatment failure?
Failure of migraine preventive therapy because of poor efficacy or tolerability is an all too common problem in clinical practice. Patients are frequently dissatisfied with available preventive treatments and compliance is poor.1 The 12-week, randomised, double-blind, placebo-controlled, phase 3b study reported in The Lancet by Uwe Reuter and colleagues2 addresses this important issue. Reuter and colleagues examine the efficacy of erenumab 140 mg (via two 70 mg injections), a monoclonal antibody targeting CGRP, compared with placebo in a population of patients aged 18–65 years who had a history of episodic migraine with or without aura for at least 12 months, had migraine symptoms for an average of 4–14 days per month during the 3 months before screening, and who had previously been treated unsuccessfully with between two and four preventive treatments.
Read more

[Articles] Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Compared with placebo, erenumab was efficacious in patients with episodic migraine who previously did not respond to or tolerate between two and four previous migraine preventive treatments. Erenumab might be an option for patients with difficult-to-treat migraine who have high unmet needs and few treatment options.
Read more

[Correspondence] Australian health professionals' statement on climate change and health
The Australian Government's contemptuous dismissal of the latest report of the Intergovernmental Panel on Climate Change (IPCC), including the panel's recommendation to dramatically reduce coal power by 2050, is unacceptable. As Australian health professionals and scientists, we are dismayed by the implications of our government's ongoing stance to disregard the consensus of the world's leading climate scientists, the precautionary principle, and any idea of duty of care regarding the future wellbeing of Australians and our immediate neighbours.
Read more